We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Veraxa Biotech GmbH and Indivumed GmbH have entered an agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer.